EMERYVILLE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NMI Holdings, Inc. (Nasdaq: NMIH) today reported net income of $96.0 million, or $1.22 per diluted share, for the third quarter ended September 30, 2025, compared to $96.2 million, or $1.21 per diluted share, for the second quarter ended June 30, 2025 and $92.8 million, or $1.15 per diluted share, for the third quarter ended September 30, 2024. Adam Pollitzer, President and Chief Executive Officer of National MI, said, “In the third quarter, we again del ...

Net Investment Income of $0.40 Per Share; Stability in Both NAV and NII Per Share NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SLR Investment Corp. (NASDAQ: SLRC) (the “Company”, “SLRC”, “we”, “us”, or “our”) today reported net investment income (“NII”) of $21.6 million, or $0.40 per share, for the third quarter of 2025. On November 4, 2025, the Company’s board of directors (the “Board”) declared a quarterly distribution of $0.41 per share payable on December 26, 2025, to holders of record as of December 12, ...

Accessibility StatementSkip Navigation THOUSAND OAKS, Calif., Nov. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2025. Â "We delivered strong volume growth this quarter, reflecting the demand for our medicines and the impact we're having on patients worldwide. With disciplined investment and a pipeline of first-in-class medicines, we're focused on expanding access, advancing innovation, and sustaining long-term growth," said Robert A. Bradway, chairma ...

Accessibility StatementSkip Navigation WARREN, N.J., Nov. 4, 2025 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ended September 30, 2025. Key Corporate Updates Key Clinical and Regulatory Updates Third Quarter 2025 Financial Highlights PTC Full-Year 2025 Financial Guidance For the full year 2025, PTC anticipates: Total revenue of $750 to $800 million, which includes in-line products and royalty revenue from Evrysdi.  ...

Completed enrollment in soquelitinib atopic dermatitis Phase 1 trial extension cohort 4 (200 mg BID dose with 8-week treatment period) with data announcement anticipated in January Soquelitinib atopic dermatitis phase 2 trial on track to initiate in early Q1 2026 Phase 3 registrational clinical trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open; final Phase 1/1b results accepted for oral presentation at the American Society of Hematolog ...

Third quarter net income of $1.49 per diluted share and adjusted operating income of $1.50 per diluted share Third quarter 2025 highlights compared to third quarter 2024, unless otherwise noted:(1) Net income increased $19.4 million to $39.2 million.Net investment income increased 6.3% to $26.0 million.Combined ratio improved 6.3 points to 91.9%; composed of an underlying loss ratio of 56.0%, catastrophe loss ratio of 1.3%, no prior year reserve development, and underwriting expense ratio of 34.6%.Underlyin ...

– Generated LUMRYZ™ net product revenue of $77.5 million, a 55% increase compared to third quarter 2024 – – Approximately 3,400 patients on LUMRYZ as of September 30, 2025, a 48% increase compared to September 30, 2024 – – Announced global settlement of all litigation with Jazz Pharmaceuticals, Inc. (“Jazz”) – – Acquisition by Alkermes plc (“Alkermes”) expected to close in first quarter 2026 – DUBLIN, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company fo ...

HOUSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Powell Industries, Inc. (NASDAQ: POWL), a leading supplier of custom engineered solutions for the management, control and distribution of electrical energy, today announced that it will release results for the fiscal fourth quarter and year ended September 30, 2025 on Tuesday, November 18, 2025 after the market closes. In conjunction with the release, Powell has scheduled a conference call, which will be broadcast live within the Investor Relations section of the C ...

Accessibility StatementSkip Navigation The Company is updating its full-year 2025 revenue guidance to between $40.3M and $40.4M, representing approximately 15% year-over-year growth at the midpoint. The Company is updating its 2025 expected adjusted EBITDA to between $9.0M and $9.1M, representing a 35% year-over-year increase at the midpoint, and expects adjusted EPS of $0.72 to $0.73 per share. Total revenue increased 15% to a record $10.2M from $8.9M in the same prior year period. Gross profit increased t ...

Annualized recurring revenue (“ARR”) of $838 million, an increase of 2% year-over-yearTotal revenue of $218 million, up 2% year-over-year; Product subscriptions revenue of $210 million, up 2% year-over-yearGAAP operating income of $5.9 million; Non-GAAP operating income of $37 millionNet cash provided by operating activities of $38 million; Free cash flow of $30 million BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Rapid7, Inc. (Nasdaq: RPD), a leader in threat detection and exposure management, today announced ...